Equity Profile

IMVT

Immunovant, Inc.

Health CareBiotechnology$6.4B

Aug10Mon

Pre-Earnings Brief

UpcomingQ1-2027Pre-Market9:00 AM EDT

Company Snapshot

Immunovant, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is crucial for future funding and development.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IMVT Q1-2027 Earnings Preview

Context

Company Snapshot

Immunovant, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases. With a market cap of $7 billion, it plays a significant role in the health care sector, particularly as demand for innovative treatments continues to rise.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.82%

Avg Stock Reaction

+4.85%

Last Quarter Recap

In the last quarter, Immunovant reported an EPS of -$0.73, which was worse than expected. Despite this, the stock saw a notable increase of over 35% the following day, suggesting strong investor interest.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Immunovant are mixed, with some investors optimistic about potential breakthroughs in clinical trials while others remain cautious due to recent earnings misses.

Bull Case

The optimistic view hinges on successful clinical trial results that could lead to new product approvals, significantly boosting revenue and market share.

Bear Case

Conversely, the pessimistic outlook is based on the company's history of earnings misses and concerns about its ability to deliver on growth promises.

Expectations

Two Questions That Matter

The print will turn on these two things.

What progress has been made in ongoing clinical trials?

Updates on clinical trials are critical as they can directly influence the company's future revenue potential and investor confidence.

How does management plan to address recent earnings misses?

Understanding management's strategy to improve performance is essential for assessing the company's future outlook and stability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of upcoming clinical trial results, which could significantly change the company’s growth narrative.

Supporting Evidence

The options market is pricing a 29.13% move, indicating high uncertainty that may not align with the actual outcomes.

Recent insider selling could suggest a lack of confidence in immediate performance, contrasting with optimistic market sentiment.

Key Risk

If clinical trial results exceed expectations, it could dramatically shift investor sentiment and stock performance.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for significant breakthroughs against the backdrop of recent performance struggles.

Bull Confirmed If

Successful results from key clinical trials that lead to product approvals would confirm the bull case.

Bear Confirmed If

Continued earnings misses and lack of clear growth strategy would solidify the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±29.13%

Historical Avg

±9.6%

Pricing rich

The options market is pricing in a significant move around the earnings report, indicating high uncertainty among investors.

Options are pricing ±29.1% while IMVT has averaged ±9.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

100.4%

Calls (69K)P/C Ratio: 0.06Puts (6K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$844,584.68

28,514 sh

2 insiders

Net

$844,584.68

Net selling

Most Active Insiders· 2 open-market trades

Chief Financial OfficerGirao Tiago
$763,011.20

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunovant beats expectations, history suggests the stock could rise by around 4.5%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may see a muted reaction as investors reassess growth potential.

Miss

A miss could lead to a decline of about 5.06%, reflecting ongoing concerns about the company's trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timelines for clinical trial results.
2Management's commentary on strategies to improve financial performance.
3Details on partnerships or collaborations that may enhance product development.
4Insights into market demand for Immunovant's therapies.
5Any guidance on future revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

Immunovant, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is crucial for future funding and development.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IMVT Q1-2027 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.82%

Avg Stock Reaction

+4.85%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Immunovant are mixed, with some investors optimistic about potential breakthroughs in clinical trials while others remain cautious due to recent earnings misses.

Bull Case

The optimistic view hinges on successful clinical trial results that could lead to new product approvals, significantly boosting revenue and market share.

Bear Case

Conversely, the pessimistic outlook is based on the company's history of earnings misses and concerns about its ability to deliver on growth promises.

Expectations

Two Questions That Matter

The print will turn on these two things.

What progress has been made in ongoing clinical trials?

Updates on clinical trials are critical as they can directly influence the company's future revenue potential and investor confidence.

How does management plan to address recent earnings misses?

Understanding management's strategy to improve performance is essential for assessing the company's future outlook and stability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of upcoming clinical trial results, which could significantly change the company’s growth narrative.

Supporting Evidence

The options market is pricing a 29.13% move, indicating high uncertainty that may not align with the actual outcomes.

Recent insider selling could suggest a lack of confidence in immediate performance, contrasting with optimistic market sentiment.

Key Risk

If clinical trial results exceed expectations, it could dramatically shift investor sentiment and stock performance.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for significant breakthroughs against the backdrop of recent performance struggles.

Bull Confirmed If

Successful results from key clinical trials that lead to product approvals would confirm the bull case.

Bear Confirmed If

Continued earnings misses and lack of clear growth strategy would solidify the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±29.13%

Historical Avg

±9.6%

Pricing rich

The options market is pricing in a significant move around the earnings report, indicating high uncertainty among investors.

Options are pricing ±29.1% while IMVT has averaged ±9.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

100.4%

Calls (69K)P/C Ratio: 0.06Puts (6K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$844,584.68

28,514 sh

2 insiders

Net

$844,584.68

Net selling

Most Active Insiders· 2 open-market trades

Chief Financial OfficerGirao Tiago
$763,011.20

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunovant beats expectations, history suggests the stock could rise by around 4.5%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may see a muted reaction as investors reassess growth potential.

Miss

A miss could lead to a decline of about 5.06%, reflecting ongoing concerns about the company's trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timelines for clinical trial results.
2Management's commentary on strategies to improve financial performance.
3Details on partnerships or collaborations that may enhance product development.
4Insights into market demand for Immunovant's therapies.
5Any guidance on future revenue expectations.